Abstract 1789P
Background
The volume of disease (high-volume disease (HVD) / low-volume disease (LVD)) as defined by the CHAARTED criteria based on conventional imaging, is associated with overall survival and used for treatment decisions in mHSPC patients. It remains unknown how the definition of HVD and LVD can be transferred to PSMA-PET imaging.
Methods
In this retrospective study that included 4 international sites, mHSPC patients who underwent a 68Ga-PSMA-11 PET/CT or PET/MRI and a BS (CI) (within a maximum time interval of 100 days) were included. Treatment in between both scans was excluded. HVD and LVD was determined on the BS and on the CT or MRI component. CHAARTED stratification into HVD and LVD was also applied to PSMA-PET. HVD was defined by the presence of visceral metastases and / or > 4 bone metastases (with > 1 beyond spine and pelvis). EXINIboneTM 3.4 (EXINI Diagnostics) was used for the number / localization of bone metastases on BS. The whole-body (WB) PSMA-PET positive tumor volume (PSMA-TV) was obtained using a semi-automatic thresholding method on Affinity 3.0.2 (Hermes Medical Solutions).
Results
Paired PSMA-PET+BS of 50 mHSPC patients were included (median PSA 43.8 (0.2 – 2840.0) ng/ml). 13/50 patients had disease detected in the prostate fossa, 25/50 in lymph nodes, 34/50 in bones and 2/50 in visceral organs by CI and 31/50, 28/50, 29/50 and 2/50 by PSMA-PET, respectively. Based on CI, 14/50 patients had CI-HVD (28%) and 36/50 CI-LVD (72%). Based on PSMA-PET, 21/50 patients had PSMA-HVD (42%) and 22/50 PSMA-LVD (44%). 7/50 (14%) patients had no PSMA-positive lesion or only in the prostate fossa while CI was at least CI-LVD. Overall, mean WB-PSMA-TV was 248.1 ml (0 – 3734.0 ml). In CI-HVD, mean WB PSMA-TV was 713.7 (0.3 – 3734.0) ml, in CI-LVD, 46.4 (0-228.0) ml. In PSMA-HVD, 518.1 (0 – 3734.0) ml and in PSMA-LVD, 59.7 (0 – 228.0) ml. Downstaging from CI to PSMA-PET occurred in in 7/50 patients (14.0%), upstaging (LVD to HVD) in 8/50 patients (16.0%).
Conclusions
Stage migration between LVD and HVD from CI to PSMA PET occurs both by up- and downstaging. Correlation with outcome will lead to new definitions of HVD/LVD based on PSMA PET/CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W. Fendler: Other, Research Funding: SOFIE Bioscience; Other, Other, Consultant, Speaker: Janssen; Other, Other, Constant, image review: Calyx; Other, Other, Consultant, speaker, research funding: Bayer; Other, Other, Consultant, speaker: Novartis; Other, Other, Speaker: Telix; Other, Other, speaker: GE, Eczacıbaşı Monrol. K. Herrmann: Financial Interests, Personal, Advisory Board: Bayer, Adacap/Novartis, Curium, Boston Scientific, GE Healthcare, AstraZeneca; Financial Interests, Personal, Invited Speaker: Sirtex, Siemens Healthineers, Monrol; Financial Interests, Personal, Other, Consultant: Amgen; Financial Interests, Personal, Other, DMSB: ymabs; Financial Interests, Personal, Advisory Board, Scientific Advisor: AdvanceCell; Financial Interests, Personal, Advisory Board, Advisor, Consultant: Janssen; Financial Interests, Personal, Advisory Board, Consultant: Eco1R; Financial Interests, Personal, Member of Board of Directors: Sofie Biosciences, Theragnostics, Pharma 15; Financial Interests, Personal, Ownership Interest: Sofie Biosciences; Financial Interests, Personal, Stocks/Shares: Aktis Oncology; Non-Financial Interests, Leadership Role, Chair Oncology&Theragnostics Committee: EANM. All other authors have declared no conflicts of interest.
Resources from the same session
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14